Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Antibodies to Remicade Cross-React with Biosimilar Remsima

Will Boggs, MD  |  

“This preliminary study cannot conclude that these two drugs are interchangeable. Finally, though the authors demonstrated that antibodies to Remicade under treatment recognize Remsima, they have not analyzed the inverse study,” said Dr, Roblin.

Celltrion funded the study, employed two of the 10 authors and provided compensation to Dr. Ben-Horin.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

    (Reuters)—A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson’s arthritis drug Remicade (infliximab) that could eventually batter sales of the branded product. The panel, by a vote of 21-3, supported use of the biosimilar from Celltrion Inc. and Pfizer Inc.,…

    Remicade Antibodies Cross-React to Biosimilars

    NEW YORK (Reuters Health)—Patients with antibodies to infliximab in Remicade should not be switched to biosimilars, researchers warn. “(The) antibodies will cross-react with the new biosimilar drug, potentially reducing clinical response,” Dr. Daniel Nagore, director of research and development at Progenika Biopharma in Derio, Spain, told Reuters Health by email. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUE“The…